Workflow
ATI Physical Therapy(ATIP) - 2024 Q3 - Quarterly Results

Financial Performance - Net revenue for Q3 2024 was 190.0million,anincreaseof7.1190.0 million, an increase of 7.1% compared to 177.5 million in Q3 2023[3] - Net patient revenue was 174.7million,up7.7174.7 million, up 7.7% from 162.3 million in Q3 2023, partly due to one additional business day[4] - Total net revenue for the nine months ended September 30, 2024, reached 559.571million,comparedto559.571 million, compared to 516.724 million for the same period in 2023, reflecting an increase of 8.3%[35] - Operating income for Q3 2024 was 1.129million,asignificantimprovementfromanoperatinglossof1.129 million, a significant improvement from an operating loss of 764 thousand in Q3 2023[35] - The company reported a net loss attributable to ATI Physical Therapy of 33.814millionforQ32024,comparedtoanetlossof33.814 million for Q3 2024, compared to a net loss of 15.197 million in Q3 2023[35] - Net loss for the nine months ended September 30, 2024, was 48,944,000,animprovementfromanetlossof48,944,000, an improvement from a net loss of 61,570,000 for the same period in 2023[38] - The net loss available to common stockholders was 40.8million,comparedto40.8 million, compared to 18.3 million in Q3 2023[13] - The company reported a net loss of 32,869inQ32024,comparedtoanetlossof32,869 in Q3 2024, compared to a net loss of 2,552 in Q2 2024[44] Revenue and Growth Metrics - Visits per Day (VPD) increased by 6.1% to 24,860 from 23,435 in Q3 2023, driven by higher clinical FTE and productivity[5] - For Q4 2024, the company projects revenue between 182millionand182 million and 192 million, with Adjusted EBITDA expected to be between 9millionand9 million and 14 million[20] - Net Patient Revenue for Q4 2023 was 166,145,representinga13.0166,145, representing a 13.0% increase from Q4 2022[40] - The number of visits per day increased to 24,238 in Q4 2023, up from 22,316 in Q4 2022, indicating a growth of 8.7%[41] - PT Revenue per Clinic for Q2 2024 reached 196,610, a 12.5% increase compared to Q1 2024[42] Cost and Expense Management - Salaries and related costs increased by 8.7% to 105.6million,primarilyduetoaddedcliniciansandwageinflation[6]Selling,general,andadministrativeexpensesdecreasedto105.6 million, primarily due to added clinicians and wage inflation[6] - Selling, general, and administrative expenses decreased to 23.772 million in Q3 2024 from 25.085millioninQ32023,showingcostmanagementefforts[35]Cashpaidforinterestwas25.085 million in Q3 2023, showing cost management efforts[35] - Cash paid for interest was 42,883,000, compared to 38,998,000inthepreviousyear,indicatinganincreaseininterestexpenses[39]LiquidityandFinancialPositionTotalliquidityasofSeptember30,2024,was38,998,000 in the previous year, indicating an increase in interest expenses[39] Liquidity and Financial Position - Total liquidity as of September 30, 2024, was 23.5 million, with a need for additional liquidity by early 2025[18] - Cash and cash equivalents decreased to 23,460,000from23,460,000 from 36,802,000, a reduction of about 36.5%[39] - Total assets decreased to 967,281,000asofSeptember30,2024,downfrom967,281,000 as of September 30, 2024, down from 1,003,281,000 at December 31, 2023, representing a decline of approximately 3.6%[36] - Total current liabilities decreased to 143,662,000from143,662,000 from 156,447,000, a decrease of about 8.2%[36] - Long-term debt increased to 441,511,000from441,511,000 from 433,578,000, an increase of approximately 1.4%[36] - Net cash used in operating activities was 31,399,000fortheninemonthsendedSeptember30,2024,comparedto31,399,000 for the nine months ended September 30, 2024, compared to 17,775,000 for the same period in 2023, indicating a worsening cash flow situation[38] Impairment and Fair Value Adjustments - Fair value remeasurement losses totaled 19.0million,comparedtoagainof19.0 million, compared to a gain of 1.9 million in Q3 2023, primarily due to share price increases[11] - The company faced a change in the fair value of 2L Notes amounting to 18.765millioninQ32024,comparedtoalossof18.765 million in Q3 2024, compared to a loss of 1.485 million in Q3 2023[35] - The company reported a change in the fair value of 2L Notes resulting in a loss of 15,976,000forthequarter[45]Thecompanyincurred15,976,000 for the quarter[45] - The company incurred 5,591,000 in goodwill, intangible, and other asset impairment charges during the quarter[45] - The company faced a significant impairment charge of 96,038,000forgoodwillandintangibleassetsin2022[46]RegulatoryandMarketEnvironmentThecompanyissubjecttoextensiveregulationandmacroeconomicuncertainty,whichmayimpactfutureperformanceandcompliance[27]EmployeeMetricsTheheadcountturnoverratedecreasedto1696,038,000 for goodwill and intangible assets in 2022[46] Regulatory and Market Environment - The company is subject to extensive regulation and macroeconomic uncertainty, which may impact future performance and compliance[27] Employee Metrics - The headcount turnover rate decreased to 16% in Q1 2024, down from 27% in Q1 2023, showing improved employee retention[41] - The average PT salaries per visit decreased to 56.68 in Q1 2024, down from 56.38inQ42023[42]AdjustedEBITDAandMarginsAdjustedEBITDAroseto56.38 in Q4 2023[42] Adjusted EBITDA and Margins - Adjusted EBITDA rose to 12.1 million, a 28.8% increase from 9.4millioninQ32023,withanAdjustedEBITDAmarginof6.49.4 million in Q3 2023, with an Adjusted EBITDA margin of 6.4%[13][14] - Adjusted EBITDA and Adjusted EBITDA margin are used to provide a clearer picture of the company's operating performance, although specific figures for these measures were not disclosed[31] - Adjusted EBITDA for Q4 2023 was 12,145, with an Adjusted EBITDA margin of 6.4%[44] - Adjusted EBITDA for Q2 2024 was 16,579,markingasignificantincreasefrom16,579, marking a significant increase from 6,463 in Q1 2024[44] - Adjusted EBITDA for the quarter was 12,675,000,withanadjustedEBITDAmarginof7.012,675,000, with an adjusted EBITDA margin of 7.0%, up from 5.3% in the previous quarter[45] - Adjusted EBITDA for the year ended December 31, 2022, was 6,363,000, with an adjusted EBITDA margin of 3.9%[46]